Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cyclerion Therapeutics ( (CYCN) ) has provided an announcement.
Cyclerion Therapeutics has renegotiated its praliciguat license agreement with Akebia, securing $1.75 million in upfront and near-term payments while reducing operating expenses to focus on building its CNS pipeline. Additionally, Cyclerion entered into a license option agreement for olinciguat with CVCO Therapeutics, marking significant steps in monetizing its legacy assets and positioning itself for future growth by acquiring new CNS assets.
More about Cyclerion Therapeutics
Cyclerion Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing drugs for the central nervous system (CNS) space. Its primary products include a portfolio of soluble guanylate cyclase (sGC) stimulators aimed at generating revenues and advancing its strategic initiatives.
YTD Price Performance: 5.37%
Average Trading Volume: 3,096,315
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.57M
See more data about CYCN stock on TipRanks’ Stock Analysis page.